Foamy virus–adenovirus hybrid vectors
- 15 January 2004
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 11 (8) , 722-728
- https://doi.org/10.1038/sj.gt.3302216
Abstract
To confer adenovirus vectors (AdV), the feature of integration into the host cell genome hybrid vectors were characterized in vitro, which express vectors derived from the prototypic foamy virus (FV) in the backbone of a high-capacity AdV. FVs constitute a subfamily of retroviruses with a distinct replication pathway and no known pathogenicity. In the absence of envelope glycoprotein, the prototypic FV behaves like a retrotransposon, while it behaves like an exogenous retrovirus in its presence. Two principle types of vectors, which either allows the intracellular (HC-FAD-7) or, in addition, the extracellular (HC-FAD-2) pathway were constructed. In both chimeras the expression of the FV vector was controlled by the tetracycline-regulatable system. Hybrids were produced close to 1010 infectious units/ml. By Southern blotting, the functionality of the hybrid vectors to generate host cell genomic integrants was shown. However, the efficiency of HC-FAD-7 to establish stable transgene expression was rather low, while around 70% of cells were stably transduced in secondary round following primary transduction with HC-FAD-2 at an MOI of 100. Given the benign characteristics of high-capacity adenovirus and FV vectors, hybrids based on HC-FAD-2 are probably suited for an in vivo application.Keywords
This publication has 42 references indexed in Scilit:
- The Replication Strategy of Foamy VirusesPublished by Springer Nature ,2003
- Improved Foamy Virus Vectors with Minimal Viral SequencesMolecular Therapy, 2002
- Improved Primate Foamy Virus Vectors and Packaging ConstructsJournal of Virology, 2002
- Efficient intracellular retrotransposition of an exogenous primate retrovirus genomeThe EMBO Journal, 2000
- Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicityNature Genetics, 1998
- Gene therapy - promises, problems and prospectsNature, 1997
- Gene therapy: Progress, problems, prospects.Nature Medicine, 1997
- A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase.Proceedings of the National Academy of Sciences, 1996
- BEL-1 Transactivator Responsive Sequences in the Long Terminal Repeat of Human Foamy VirusVirology, 1993
- The transcriptional transactivator of human foamy virus maps to the bel 1 genomic region.Proceedings of the National Academy of Sciences, 1991